This protocol outlines a minimally invasive and quickly performed approach for transgene delivery in the extracranial nervous system of adult mice using recombinant adeno-associated virus (AAV). The technique, named Sciatic Nerve Direct Immersion (SciNDi), relies on the direct bilateral immersion of the exposed sciatic nerve with AAV. We show that in comparison with intramuscular AAV delivery, SciNDi results in widespread transduction in connected neuroanatomical tracts both in the sciatic nerve trunk and the lumbar spinal cord.
Protocol

Recombinant adeno-associated virus mediated gene delivery in the extracranial nervous system of adult mice by direct nerve immersion

Mette Richner,1,4,* Nádia Pereira Gonçalves,1 Poul Henning Jensen,3 Jens Randel Nyengaard,2 Christian Bjerggaard Vægter,1 and Asad Jan3,5,*

1Danish Research Institute of Translational Neuroscience (DANDRITE), Nordic-EMBL Partnership for Molecular Medicine, Aarhus University, Høegh-Guldbergs Gade 10, 8000 Aarhus C, Denmark
2Core Center for Molecular Morphology, Section for Stereology and Microscopy Department of Clinical Medicine, Aarhus University, Department of Pathology, Aarhus University Hospital, 8200 Aarhus N, Denmark
3DANDRITE, Department of Biomedicine, Aarhus University, Ole Worms Allé 3, 8000 Aarhus C, Denmark
4Technical contact
5Lead contact
*Correspondence: ajan@aias.au.dk (A.J.), mette.richner@biomed.au.dk (M.R.)
https://doi.org/10.1016/j.xpro.2022.101181

SUMMARY
This protocol outlines a minimally invasive and quickly performed approach for transgene delivery in the extracranial nervous system of adult mice using recombinant adeno-associated virus (AAV). The technique, named Sciatic Nerve Direct Immersion (SciNDi), relies on the direct bilateral immersion of the exposed sciatic nerve with AAV. We show that in comparison with intramuscular AAV delivery, SciNDi results in widespread transduction in connected neuroanatomical tracts both in the sciatic nerve trunk and the lumbar spinal cord.
For complete details on the use and execution of this protocol, please refer to Jan et al. (2019) and Richner et al. (2011, 2017).

BEFORE YOU BEGIN
AAV are engineered pseudotyped viral particles, derived from the native AAV (of the single-stranded DNA Parvovirinae family), and are widely used for gene delivery applications in vivo (Hocquemiller et al., 2016; Bedbrook et al., 2018; Wang et al., 2019). Based on their low immunogenicity profile and versatile capabilities for achieving transduction in several tissues, they have emerged as preferred vehicle for gene therapy applications (Bedbrook et al., 2018; Hudry and Vandenberghe, 2019; Wang et al., 2019). For this purpose, AAVs are delivered directly into the target tissue (i.e., intraparenchymal) or via peripheral routes (e.g., intramuscular, intravenous) to achieve local or more widespread transduction (Stoica et al., 2013). In this regard, direct intraparenchymal injection remains the preferred approach for AAV delivery into the nervous system of adult mice (e.g., brain, spinal cord, spinal nerves, DRG) (Naso et al., 2017; Bedbrook et al., 2018; Hocquemiller et al., 2016).
The advantage of intraparenchymal delivery is that the transduction is predominantly localized at the site of injection, which limits potential undesirable effects in other tissues/regions that may present as confounding factors in data interpretation. However, this approach involves invasive procedures and is potentially limited in certain delivery aspects such that widespread transduction in peripheral nervous system is a significant challenge (Bedbrook et al., 2018; Hocquemiller et al., 2016; Tosolini and Sleigh, 2020; Yu et al., 2016). For example, direct nerve, DRG or intra-spinal injections are usually performed using 1–2 μL AAV load with the aim to achieve local transduction in neurons or glial cells (Homs et al., 2011), and specificity can be increased by AAV design incorporating cell-specific regulatory elements (Yu et al., 2016). In comparison, AAV mediated gene delivery in adult nervous
system using peripheral routes remains an evolving field (Bedbrook et al., 2018; Hoyng et al., 2015). Since the focus of this manuscript is an experimental protocol, we are unable to provide a detailed discussion on advantages and efficacy of different peripheral routes of AAV delivery into rodents—e.g., intramuscular (Towne et al., 2009), intraperitoneal (Dane et al., 2013), intravenous (Gessler et al., 2019), intra-nerve (Homs et al., 2011) and into dorsal root ganglia (DRG) (Yu et al., 2016), and the reader is encouraged to consult some recent review articles elsewhere for in-depth discussion and specific research studies (Tosolini and Sleigh, 2020; Hoyng et al., 2015; Wang et al., 2019; Gessler et al., 2019; Naso et al., 2017; Mason et al., 2011; Bedbrook et al., 2018; Hocquemiller et al., 2016; Samulski and Muzyczka, 2014). In summary, the above cited examples show that peripheral routes of AAV delivery can be utilized for achieving optimal levels of transgene expression in the nervous system, either within the local neuroanatomical structures (e.g., in peripheral nerve terminals and neurons within the DRG or spinal cord following intramuscular injection (Jan et al., 2019; Towne et al., 2009; Tosolini and Sleigh, 2020)) or more distally (e.g., spinal cord or brain following intravenous (Gessler et al., 2019; Mason et al., 2011; Bedbrook et al., 2018; Hocquemiller et al., 2016; Samulski and Muzyczka, 2014)).

Several laboratories, including our own, have attempted to refine the AAV delivery for targeting structures in the rodent nervous system using peripheral routes capitalizing on the retrograde transduction capability of AAV, both using conventional AAV serotypes as well as newly engineered retro-AAV (Chen et al., 2020; Chan et al., 2017; Jan et al., 2019; Tervo et al., 2016). Previously, we have studied transgene (i.e., enhanced green fluorescent protein-eGFP) delivery into the extracranial nervous system of adult mice by intramuscular (IM) injection, and compared three commonly used serotypes (AAV2/6, AAV2/8 and AAV2/9) with eGFP expression driven by either the ubiquitous cytomegalovirus (CMV) promoter or neuron-specific synapsin (hSyn) promoter (Jan et al., 2019). Here, we present a significant refinement in our attempts at peripheral AAV delivery for targeting structures in the nervous system via direct immersion of a peripheral nerve, using sciatic nerve as the proof-of-concept site—hence the acronym Sciatic Nerve Direct Immersion (SciNDi) (see Figure 1). Using a AAV2/6 (CMV:eGFP) vector, our data show that bilateral SciNDi led to significantly improved AAV delivery in the sciatic nerve, in comparison with bilateral hindlimb IM delivery. Furthermore, enhanced transgene (eGFP) expression was observed in sciatic nerve, and discrete instances of eGFP positive neurons and neuronal processes were detected in the lumbar spinal cord (See Figures 2A–2I; also see expected outcomes). Based on these observations, we consider that the procedure is of potential interest to researchers exploring the transgene delivery and/or manipulation of gene expression in local structures (i.e., sciatic nerve, DRGs, spinal cord- ventral horn), especially in situations where a minimum procedure-induced trauma in nervous structures is desired. However, it is worthwhile mentioning that the described protocol intends to provide a technique for modestly improved transgene delivery into the sciatic nerve and connected neuroanatomical structures, including muscle tissue, relying on the transgene (i.e., eGFP) expression driven by the ubiquitous CMV promoter. Nonetheless, for the reader’s benefit we have alluded to examples from published literature throughout the text below that can serve as a guide in situations where specificity for targeting discrete cell populations is desired.

The protocol below primarily describes the specific steps for using AAV2/6 application in adult mice. Nevertheless, the protocol could also potentially be adapted for application in other rodents, as well as in rodents of various ages. In these experiments, bilateral SciNDi or hindlimb IM injections were performed in 2–3 months old mice using 2.8e10 AAV particles (serotype, AAV2/6; promoter:transgene insert, CMV:eGFP; volume, 10 µl) and were euthanized 4 weeks post-procedure for tissue collection and further analyses.

**Note:** Throughout this manuscript, AAV refers to recombinant AAV and is not to be confused with retro-AAV and/or retrograde transduction.

INSTITUTIONAL AUTHORIZATION. All animals were handled in full compliance with Danish and European regulations, under the authorization 2017-15-0201-01203 (issued to PHJ, co-author).
Preparation of equipment

**Timing:** 60 min

1. Sterilize the surgical equipment by autoclave.
2. Secure sterile 2–10 μL filtered pipette tips.
3. Transfer an aliquot of AAV particles (stored at −80°C) and thaw on ice. Consult the guidelines from AAV production facility for handling and use. In this protocol, we have used AAV2/6 by the Iowa Viral Vector Core and the relevant guidelines are listed on the website [https://medicine.uiowa.edu/vectorcore/technical-resourcesfaq](https://medicine.uiowa.edu/vectorcore/technical-resourcesfaq). In the current example, the aliquots were 25 μL/tube and thawed on ice approximately for 10–15 min until a liquid suspension was clearly visible.

**CRITICAL:** Ensure aseptic equipment and a clean work area in a surgical facility for the animals throughout the procedure. Keep the thawed AAV suspension on ice throughout the procedure. Desired titers of AAV particles should be adjusted by dilution in sterile phosphate-buffered saline (PBS). Also see troubleshooting, problem 1.

### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| eGFP, Rabbit polyclonal | Cell Signaling Technologies | Cat# 25555 |
| Working dilution, 1:500 |        |            |
| eGFP, Chicken polyclonal | Abcam | Cat# ab13970 |
| Working dilution, 1:200 |        |            |
| Neurofilament light chain (NF-L), Mouse monoclonal | Cell Signaling Technologies | Cat# 2835 |
| Working dilution, 1:200 |        |            |
| S100 (Schwann cell marker), Rabbit monoclonal | DAKO | Cat# Z0311 |
| Working dilution, 1:200 |        |            |
| CD68 (Monocyte macrophage marker), rat monoclonal Working dilution, 1:200 | Novus Biologicals | Cat# NBP2-33337 |
| **Bacterial and virus strains** |        |            |
| Recombinant adeno-associated vector (rAAV) | Iowa Vector Core, Iowa University | Iowa-S47 |
| **Chemicals, peptides, and recombinant proteins** |        |            |
| Meloxicam (analgesic) | Boehringer Ingelheim | Cat# EU2/97/004/006; CAS:71125-38-7 |
| Temgesic (analgesic) | Indivior Europe Limited | Cat# 521634; CAS:52485-79-7 |
| Xylocaine 2% (analgesic) | Aspen Pharma Ireland Limited | Cat# 453053; CAS: 137-58-6 |
| Isoflurane (furane) IsoFlo Vet 100% | Abbott | Cat# 002185; CAS: 26675-46-7 |
| Betadine | Avrio Health | Cat# NDC 67618-154-16 |
| 3,3’-diaminobenzidine (DAB) | Electron Microscopy Sciences | Cat# 13080 |
| Haematoxylin (Mayer) | Sigma-Aldrich | Cat# 51275 |
| Ophthalmic ointment | Ophtha | Cat# 53 96 68 |
| Sterile PBS | GIBCO | Cat# 10010-015 |
| Sterile saline | Fresenius Kabi AB | Cat# 141856 |
| Sterile cotton-tipped applicator | E-vet A/S | Cat# 140041 |
| **Experimental models: Organisms/strains** |        |            |
| Mice: Wild type C57bl6/J (2–3 months old, both sexes) | Janvier, France | C57bl6/J |
| **Other supplies** |        |            |
| Isoflurane vaporizer | E-vet A/S | Cat# 905050 |

(Continued on next page)
**STEP-BY-STEP METHOD DETAILS**

### Anesthesia

© Timing: 5 min

This step ensures deep anesthesia of the mouse, which is required for the surgical procedure.

1. Anesthetize the adult mouse (2–3 months old; male or female) using an anesthetic vaporizer to administer an inhalation agent (e.g., isoflurane), preferably in a ventilated fume hood. Alternatively, use a small induction chamber/container for induction in accordance with institution guidelines, and minimize human exposure.

2. Confirm surgical level of anesthesia by gently pinching the tail or paw with unserrated forceps. Do not proceed until the mouse is unresponsive to the pinch.

3. Using a cotton-tipped applicator, generously apply ophthalmic ointment onto both eyes.

**ALTERNATIVE TO ISOFLURANE ANESTHESIA:** Injectable regimens, e.g., 75 mg/kg ketamine plus 1 mg/kg medetomidine can also be used as outlined previously (Stoica et al., 2013). Consult the anesthesia dosage according to veterinary guidelines for species, size and age. In comparison with the inhalation agents, the injectable regimens are associated with much longer duration of anesthesia, hence sufficient ophthalmic ointment and postoperative care are required, i.e., subcutaneous fluid administration, heating pad under the cage.

### Preparation of surgical area on upper hindlimb

© Timing: 2 min

This step prepares the surgical area on the upper hindlimb of the mouse for surgery. Initially, the fur is removed using either a scalpel or an electrical rodent shaver, based on the user’s preference. If using an electrical rodent shaver, the user can skip step 4 below.

4. Spray the fur along both hindlimbs with 70% ethanol to control the fur.

5. Using a scalpel or an electrical rodent shaver, remove the fur on the hindlimb in an area extending from slightly below the knee up to the hip region, as illustrated in the Figure 1A.

6. Disinfect the surgical area with an iodine containing solution (e.g., betadine). Wait for 15 s so that the applied betadine is dried on the skin.

**ALTERNATIVE TO BETADINE:** If betadine is not accessible, 70% ethanol can alternatively be used in a similar fashion.

### REAGENT or RESOURCE SOURCE IDENTIFIER

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Unserrated Forceps, Dumont, # 3 | F.S.C. (Fine Science Tools) | Cat# 11231-30 |
| Pipette, 1–10 μL volume | Thermo Fisher Scientific | Cat# 4642030 |
| Pipette tip, filtered, 10 μL | Thermo Fisher Scientific | Cat# 94052000 |
| Scalpel; Swann-Morton surgical blade no. 11 | Swann-Morton | Cat# REF0203 |
| Scissors, straight, type 3, 25 mm cutting edge | Bochem | Cat# 4070 |
| Standard syringes, 1 mL | Terumo | Cat# MDSS01SE |
| Syringe needle 27 G | Terumo | Cat# AN*2716R1 |
| Tissue adhesive | Klinibond | Cat# 115 500 |

**Software and algorithms**

| Source | Identifier |
|--------|------------|
| Prism  | https://www.graphpad.com/scientific-software/prism/ |
Exposure of the trifurcation site of sciatic nerve

**Timing:** 5 min

This step is performed to surgically expose the sciatic nerve such that the sciatic nerve trifurcation site lies in the center of the surgical field (highlighted with the dashed circle in Figures 1B and 1C), ensuring a consistent anatomical reference point (spot) for the application of AAV particles (Richner et al., 2011; Bala et al., 2014; Savastano et al., 2014).

7. Orient the hindlimb in a slightly elevated position and secure with surgical tape onto underlying surface for optimal nerve exposure (Richner et al., 2011). **OPTIONAL:** Readers may consider the injection of a local anesthetic (e.g., lidocaine) into the biceps femoris muscle according to the dosage advised by the local veterinarian.

8. Having located the knee joint and thigh bone (femur), make a small (approx. 3–5 mm) longitudinal incision in the dermal layer proximal to the knee joint with a scalpel.

9. Further open the skin by blunt dissection using the tip of a pair of scissors.

10. Now, carefully separate the muscle layer close to femur by blunt dissection with a pair of scissors, revealing the trifurcation site of the sciatic nerve, exposing approx. 5 mm of the nerve structure above and approx. 5 mm below the trifurcation site (Richner et al., 2011).

See troubleshooting, problem 2 and problem 3.

AAV application

**Timing:** 30 s

With this step, AAV particles are applied directly onto the sciatic nerve trifurcation site exposed in step 10.

11. Briefly vortex (approx 3–5 s) the freshly thawed aliquot of AAV particles and avoid repetitive pipetting.

12. Keep the thawed AAV suspension on ice throughout the procedure.

13. Aspirate desired volume ((in the range of 2–10 µL; (Jan et al., 2019; Towne et al., 2009)) with a filtered pipette tip.

14. Using an unserrated forceps, gently open the separated muscles (Figure 1B), then drop-wise (e.g., 1 drop every 2 s) apply the AAV suspension onto the sciatic nerve trifurcation site without touching the nerve (Figure 1C).

15. A co-worker may facilitate the rapid application of AAV, i.e., by loading the pipette with AAV suspension while the surgeon performs nerve exposure (Figures 1B and 1C), and immediate muscle closure post-application, so that the risk of the exposed nerve becoming dry is minimized. In this manner, the step 14 of the procedure usually takes 5–10 s.

16. Avoid repetitive touching of the nerve and do not insert any foreign material into the incision, e.g., under the nerve to restrict the diffusion of AAV solution as it may damage the delicate nerve tissue. See troubleshooting, problem 4.
**Closing of the surgical wound**

- Timing: 5 min

This step describes closing of the surgical wound.

17. Gently appose the muscle layers for approximately 10 s with the tip of an unserrated forceps. This allows for smooth diffusion of AAV particles around the nerve trunk.

18. Close the skin wound using a veterinarian approved tissue adhesive (alternatively sutures).

**Post-operative analgesic treatment and monitoring**

- Timing: 30 s

This step describes post-operative care and monitoring.

19. Inject an analgesic solution subcutaneously (e.g., non-steroidal anti-inflammatory drug, NSAID), and apply a local analgesic (e.g., lidocaine) according to national and institutional guidelines.

20. After returning the mouse into its home cage, monitor for approximately 2 h for any signs of unexpected discomfort and pain (restricted mobility, shivering, and vocalizations, biting the closed wound). See troubleshooting, problem 3.

- **Pause point:** House the mice in your animal facility for 3–6 weeks post-procedure, and then proceed to assess the AAV delivery and transgene expression in the tissue(s) of interest (see below).

**Tissue isolation for AAV delivery and gene expression analyses**

- Timing: 10–20 min

This step describes isolation of tissues for further analyses. Duration of the isolation process varies according to the desired tissues, including sciatic nerve, DRG, lumbar spinal cord and local muscle tissue (Jan et al., 2019; Richner et al., 2017).

21. Euthanize the mouse according to institutional guidelines.

22. Create a similar intramuscular space by blunt dissection (step 10 above) and collect the trunk of sciatic nerve (extending from its emergence at the sciatic notch to the trifurcation in the popliteal fossa behind the knee joint (Jan et al., 2019; Bala et al., 2014; Richner et al., 2011; Savastano et al., 2014).

23. Dissect and collect a piece of biceps femoris muscle (50–100 mg), using a forceps and a small scissor. A small piece (50–100 mg) of liver may be dissected and collected (using a forceps and small scissor) as a control tissue for gene and/or protein expression studies.

24. Isolate DRG and spinal cord tissue as illustrated previously (see accompanied video demonstration in (Richner et al., 2017).

25. Process the collected tissue(s) for gene and/or protein expression, microscopy and desired assays relevant to interest (Benkhelifa-Ziyyat et al., 2013; Chen et al., 2020; Dane et al., 2013; Jan et al., 2019).

**EXPECTED OUTCOMES**

In this manuscript, we have outlined a step-by-step procedure of AAV delivery in rodents using direct immersion of sciatic nerve with AAV2/6, for targeting of local neuroanatomically connected structures (i.e., muscle, nerve, DRG and spinal cord). Several research laboratories, including our own, have previously exploited the IM route of AAV delivery for this purpose. Extending these...
efforts, we illustrate the efficacy of AAV2/6 mediated gene delivery by SciNDi or IM route in adult mice. Accordingly, we compared AAV2/6 delivery and transgene (eGFP) expression following intramuscular (IM) AAV injection in hindlimb biceps femoris (Jan et al., 2019) and SciNDi in adult- wild type, male- C57BL6/J mice. Briefly, 2–3 months old mice were bilaterally inoculated with $2.8 \times 10^9$ AAV particles (serotype, AAV2/6; promoter, CMV:eGFP; volume, 10 $\mu$L) and were euthanized 4 weeks post-procedure for tissue collection and further analyses (examples in Figures 2 and 3).

We observed pronounced green coloration, indicative of eGFP expression in muscle tissue around the application site, both by IM or SciNDi (Figure 2A). In contrast, robust GFP expression in the lower hindlimb musculature was also observed following SciNDi, suggesting either widespread transduction in the region of sciatic nerve innervation or possibly that the AAV particles reach lower leg region through an undefined route, (Figure 2A; compare IM and SciNDi). One possibility is that the AAV that was not absorbed by the sciatic nerve could diffuse into lower hindlimb after the muscle has been closed (step 17). Then, we assessed viral genome (AAV2-ITR) and transgene (eGFP) expression in select tissues (i.e., muscle, sciatic nerve, DRG, spinal cord, brain and liver). By qRT-PCR analyses, we detected slightly higher AAV2-ITR (Figure 2B, ~1.2-fold higher AAV2-ITR in SciNDi) and eGFP mRNA expression (Figure 2C, ~1.5-fold eGFP mRNA) in the biceps femoris muscle in the SciNDi cohort. This is not surprising as IM injection leads to localized transduction in the vicinity of the injection site, while SciNDi allows the diffusion of applied AAV particles over relatively larger surface area as indicated by expression of eGFP in the muscle tissue (Figure 2A, notice the difference between IM and SciNDi). qRT-PCR analyses of the sciatic nerve, in contrast, showed considerably higher (mean, >5-fold) levels of AAV genome (Figure 2B, AAV2-ITR; also compare Muscle and Sc. nerve) and eGFP mRNA expression (mean, >16-fold) in the trunk of sciatic nerve with SciNDi compared to the IM injection (Figure 2C, eGFP mRNA; also compare Muscle and Sc. nerve).

We also examined eGFP epifluorescence in L4 DRGs, which give rise to sensory fibers in sciatic nerve, and observed scant eGFP immunodetection, either by SCI NDi or IM injection (Figure 2D; only L4 DRGs from the left side are shown). This is not surprising as peripheral AAV injections are less efficient means of AAV delivery into the DRGs compared with intra-nerve or intra-DRG injections (Homs et al., 2011; Jan et al., 2019; Towne et al., 2009; Yu et al., 2016). Microscopic analyses also revealed enhanced eGFP expression, reflected by eGFP epifluorescence along the length of sciatic nerve in the hindlimb (i.e., between the hip joint and the knee) (Compare Figure 2E- IM injection in biceps femoris with Figure 2F-SciNDi); Also compare Figure 3A- phosphate-buffered saline, PBS cohort). Furthermore, we also detected discrete instances of eGFP immunopositivity within neuronal cell bodies and intra-grey matter nerve cell processes in the lumbar ventral horn following AAV delivery via SciNDi, which was more pronounced compared with IM delivery (Figures 2G–2I; bilateral SciNDi AAV2/6 application; only left ventral horn L4/L5 is shown; also see Figure 3B, showing right ventral horn). Lastly, we did not observe eGFP immunostaining in the spinal lumbar dorsal horn (Figure 3B) using SciNDi, suggesting either lower AAV delivery and/or different transduction efficiency in the sensory interneuron populations.

These observations highlighted above (Figure 2) support the effects of AAV particles in the immediate vicinity of sciatic nerve, since we found negligible systemic AAV dissemination in qRT-PCR analyses of lumbar spinal cord, whole brain and liver (Figures 3C and 3D). Double immunofluorescence studies showed that, while eGFP was clearly detected along substantial proportion of neurofilaments in sciatic nerve, eGFP detection in Schwann cells was negligible (Compare Figure 2F- NF-L co-detection, with Figure 3E- S100 Schwann cell marker co-detection). Lastly, we did not observe inflammatory response following AAV application using SciNDi, as assessed by the co-detection of phagocyte marker CD68, either in sciatic nerve (Figure 3F), or the muscle tissue in upper hindlimb (Figures 3G–3I), indicating significant lack of tissue damage/inflammation using this technique.
QUANTIFICATION AND STATISTICAL ANALYSIS

The data were statistically analyzed in GraphPad Prism software (version 9), and the final graphs were prepared in Microsoft Excel. Statistical significance was calculated by the analysis of variance (ANOVA) or pair-wise comparisons using Mann–Whitney U test, as indicated in the figure legends.
LIMITATIONS

Development and validation of SciNDi for AAV delivery in rodent is a very recent refinement, and several aspects regarding the limitations and utility of the approach remain to be explored: 1) Targeted delivery of a functional transgene or gene-silencing constructs selectively in neuronal or glial populations, such as by using neuron-specific promoters and or selective targeting of Schwann cells; 2) Utility of SciNDi in achieving targeted gene delivery in brain structures, potentially using a large cranial nerve such as vagus with possibility of modulating visceral physiology and autonomic dysfunction in relevant models; and 3) Cross comparison of commonly used neurotropic AAV.
serotypes with AAV serotypes showing superior capability for retrograde transduction (Tervo et al., 2016; Chen et al., 2020; Cushnie et al., 2020; Samulski and Muzyczka, 2014); and 4) Lastly, longitudinal analyses of stability and/or retrograde propagation of transgene expression over protracted durations (i.e., 2, 3 and 4 months), for instance, in higher brain regions with descending projections to spinal cord (i.e., brainstem, motor cortex).

**TROUBLESHOOTING**

**Problem 1**
The study involves a different AAV construct (serotype, promoter, transgene), and not AAV2/6 (CMV:eGFP) (step 11).

**Potential solution**
Pilot experiments for determining the efficacy of other AAV constructs for specific experimental readouts may be needed. For example: i) choosing a neuronal (e.g., synapsin) or glial specific promoter (e.g., GFAP) (Gessler et al., 2019), ii) optimal titer and iii) time of tissue collection post-procedure. To demonstrate AAV delivery using SciNDi technique, we used tissue collected four weeks post-procedure to provide a comparison with our IM delivery data, collected in a similar fashion in the current manuscript and in our previously published data on AAV2/6, AAV2/8 and AAV2/9 (Jan et al., 2019). As mentioned under problem 1, the readers are also encouraged to consult relevant literature on factors affecting AAV tropism and recent developments in the refinements in vector design for applications in nervous system (Bedbrook et al., 2018; Hudry and Vandenberghe, 2019; Hocquemiller et al., 2016).

**Problem 2**
Bleeding occurs during the blunt dissection of hindlimb muscle layers (step 10).

**Potential solution**
Whenever possible, perform blunt dissection through the muscular layer instead of cutting through the muscle, as it allows faster wound healing (Fossum, 2019) and easy identification of anatomical structures. The reader is also encouraged to watch a video demonstration of this procedure (Richner et al., 2011). Do not use excessive force as that may tear blood vessels in the vicinity. If bleeding occurs, apply cotton-tipped applicators or pieces of gauze to absorb the blood. Press gently until the bleeding stops. Ensure maintained anesthesia if using anesthetic vaporizer.

**Problem 3**
The animal exhibits signs of discomfort post-procedure (step 20).

**Potential solution**
The mice should recover fully within 10–15 min once removed from the anesthesia and transferred to their house cages. If any signs of discomfort (mentioned above) persist two hours after NSAID administration, subcutaneously inject a stronger analgesic, e.g., opioids, and continue to observe the animal by direct inspection, according to national and institutional guidelines. This can be the case if the operating person has inadvertently induced muscle damage while dissection or tearing of the blood vessels in the vicinity.

If performed correctly, the procedure (i.e., opening the muscle layer by blunt dissection) is not associated with muscle damage or reduced mobility. However, we advise the readers as the following: i) watch the video demonstration for the procedure of exposing sciatic nerve using blunt dissection carefully (Richner et al., 2011) and ii) perform a trial SciNDi procedure in 4–6 mice and observe for signs of muscle damage post-procedure in close consultation with your veterinarian, i.e., inflammation and delayed wound healing or reduced mobility. If such training trials are not possible, we advise the reader to exclude animals from the experiment that show signs of discomfort and pain (restricted mobility, shivering, and vocalizations, biting the closed wound) despite NSAID
administration and treatment advised by the local veterinarian. This is partly because local bleeding, inflammation, tissue edema may induce variability in the spreading of AAV in the vicinity of the sciatic nerve, e.g., AAV diffusion into circulation due to the damaged vessels.

**Problem 4**
AAV diffusion leads to the transduction of non-neural tissues.

**Potential solution**
This issue is not specific to SciNDi as other common peripheral of AAV delivery routes (for example IM, intravenous or intraperitoneal) are also associated with such off-target effects in peripheral tissues (Towne et al., 2009; Gessler et al., 2019; Ai et al., 2017). This can be circumvented by using AAV constructs in which the transgene expression is driven by neuron-specific promoters (e.g., synapsin) instead of a ubiquitous promoter such as CMV used in this protocol (see also (Jan et al., 2019; Gessler et al., 2019)). We have outlined SciNDi primarily as a procedure for modestly increased transgene delivery in adult mice (as compared to the IM route—Figures 2 and 3), thus the readers need to optimize the efficiency of their AAV constructs (if not using AAV2/6; CMV:eGFP) and specificity of transgene expression in the desired tissues.

**Problem 5**
Expected gene expression is not observed (step 25).

**Potential solution**
Several factors are known to affect the transduction efficiency by AAV in a given tissue and/or cell populations, including: i) the AAV preparation (e.g., titer and purity), ii) AAV tropism (promoter, size and nature of the transgene) and iii) specific factors related to the procedure (e.g., AAV accessibility to the nerve tissue, duration of experiment etc.). For optimal results, obtain high purity, high titer AAV particles in small aliquots (e.g., 25 μL), avoid repetitive freeze-thaw cycles, and always keep on ice (for thawing and throughout the procedure). To ensure optimal immersion of sciatic nerve, the ideal volumes for SciNDi are 8–10 μL and should be no less than 2 μL.

The readers are also encouraged to consult relevant literature on factors affecting AAV tropism and challenges on using the peripheral routes of AAV delivery, several of which are discussed in the review articles cited in Bibliography (Tosolini and Sleigh, 2020; Hoyng et al., 2015; Wang et al., 2019; Gessler et al., 2019; Naso et al., 2017; Mason et al., 2011; Bedbrook et al., 2018; Hocquemiller et al., 2016; Samulski and Muzyczka, 2014). Lastly, the readers are also encouraged to watch our video demonstration of the sciatic nerve exposure and familiarize themselves with local anatomical structures in the hindlimb (Bala et al., 2014; Richner et al., 2011; Savastano et al., 2014).

**Problem 6**
Bilateral AAV application does not generate intra-individual control tissue (step 25).

**Potential solution**
SciNDi can be performed unilaterally, especially if the target tissue is ipsilateral sciatic nerve and/or DRGs. In these scenarios, contralateral neuromuscular tissues (i.e., hindlimb muscles, sciatic nerve, DRG) can be collected as the corresponding controls. However, when applied unilaterally, caution should be exercised in data interpretation from the contralateral side, especially spinal cord tissue, as common AAV serotypes have been found to exhibit variable degrees of hematogenous spreading (Towne et al., 2009; Benkhelifa-Ziyyat et al., 2013), or even transduction of the contralateral spinal ventral horn as an epiphenomenon of potent retrograde transduction (Chen et al., 2020).

Hence, we recommend bilateral application of AAV using SciNDi, if optimal targeting of spinal cord is desired. This is to avoid not only the potential confounding aspects of contralateral spreading (if any) indicated above, but also that bilateral AAV delivery enables administration of twice as much...
AAV particles compared with unilateral delivery. In this regard, it is also worthwhile to mention that the AAV2/6 has been shown to exhibit some degree of retrograde transduction, hence in our opinion, the reader should incorporate these factors in decision-making regarding the choice of vector. Additional controls may include the tissues dissected from animals injected bilaterally with vehicle.

**RESOURCE AVAILABILITY**

**Lead contact**

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Asad Jan (ajan@aias.au.dk).

**Materials availability**

This study did not generate any new unique reagents.

**Data and code availability**

All of the data generated and analyzed during this study are included in the main manuscript and the associated figures (Figures 2 and 3).

**ACKNOWLEDGMENTS**

This work was supported by funding to A.J. in the form of a Marie Skłodowska Curie Fellowship from the European Union’s Horizon 2020 Research and Innovation Programme (MSCA-IF-2017, grant #786433) and Lundbeckfonden, Denmark (grant #R250-2017-1131). M.R. was funded by Lundbeckfonden, Denmark (grant #R313-2019-606) and J.N.R. was supported by the Villum Foundation and Henny Sophie Clausen og møbelarkitekt Aksel Clausens Fond. The authors would like to thank Helene Andersen (JRN lab) and Sandra Bonnesen (CV lab) for technical help during the study.

**AUTHOR CONTRIBUTIONS**

M.R. and A.J. designed and performed research; C.B.V., P.H.J., and J.R.N. contributed with infrastructural support and data evaluation; M.R., N.P.G., and A.J. wrote the manuscript; M.R. and A.J. drafted the graphical abstract using BioRender, under license to C.V. (co-author). All authors read and approved the manuscript.

**DECLARATION OF INTERESTS**

The authors declare no competing interests.

**REFERENCES**

Ai, J., Li, J., Gessler, D.J., Su, Q., Wei, Q., Li, H., and Gao, G. (2017). Adeno-associated virus serotype rh.10 displays strong muscle tropism following intraperitoneal delivery. Sci. Rep. 7, 40336.

Bala, U., Tan, K.L., Ling, K.H., and Cheah, P.S. (2014). Harvesting the maximum length of sciatic nerve from adult mice: a step-by-step approach. BMC Res. Notes 7, 714.

Bedbrook, C.N., Deverman, B.E., and Gradinaru, V. (2018). Viral strategies for targeting the central and peripheral nervous systems. Annu. Rev. Neurosci. 41, 323–348.

Benkhelifa-Ziyyat, S., Besse, A., Roda, M., Ducque, S., Astord, S., Carcenac, R., Marais, T., and Barkats, M. (2013). Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice. Mol. Ther. 21, 282–290.

Chan, K.Y., Jung, M.J., Yoo, B.B., Greenbaum, A., Ravi, N., Wu, W.L., Sanchez-Guardado, L., Lois, C., Mazmanian, S.K., Deverman, B.E., and Gradianu, V. (2017). Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat. Neurosci. 20, 1172–1179.

Chen, Z., Fan, G., Li, A., Yuan, J., and Xu, T. (2020). rAAV2-retro enables extensive and high-efficient transduction of lower motor neurons following intramuscular injection. Mol. Ther. Methods Clin. Dev. 17, 21–33.

Cushnie, A.K., El-Nahal, H.G., Bohlen, M.O., May, P.J., Basso, M.A., Grimaldi, P., Wang, M.Z., De Velasco, E.M.F., Sommer, M.A., and Hellbrunner, S.R. (2020). Using rAAV2-retro in rhesus macaques: promise and caveats for circuit manipulation. J. Neurosci. Methods 345, 108859.

Dane, A.P., Woywo, S.J., Cunningham, S.C., and Alexander, I.E. (2013). Comparison of gene transfer to the murine liver following intraperitoneal and intraportal delivery of hepatotropic AAV pseudotyped serotypes. Gene Ther. 20, 460–464.

Fossum, T.W. (2019). Small Animal Surgery (Elsevier, Inc).

Gessler, D.J., Tai, P.W.L., Li, J., and Gao, G. (2019). Intravenous infusion of AAV for widespread gene delivery to the nervous system. Methods Mol. Biol. 1950, 143–163.

Hocquemiller, M., Giersch, L., Audrain, M., Parker, S., and Cartier, N. (2016). Adeno-associated virus-based gene therapy for CNS diseases. Hum. Gene Ther. 27, 478–496.

Homs, J., Ariza, L., Pages, G., Udina, E., Navarro, X., Chillón, M., and Bosch, A. (2011). Schwann cell targeting via intrasciatric injection of AAV8 as gene therapy strategy for peripheral nerve regeneration. Gene Ther. 18, 622–630.

Hoyn, S.A., De Winter, F., Tannemaat, M.R., Blits, B., Maliesz, M.J., and Verhaagen, J. (2013). Gene therapy and peripheral nerve repair: a perspective. Front. Mol. Neurosci. 6, 32.
Hudry, E., and Vandenberghe, L.H. (2019). Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron 101, 839–862.

Jan, A., Richner, M., Vaegter, C. B., Nyengaard, J. R., and Jensen, P. H. (2019). Gene transfer in rodent nervous tissue following hindlimb intramuscular delivery of recombinant adeno-associated virus serotypes AAV2/6, AAV2/8, and AAV2/9. Neurosci. Insights 14, 1179069519889022.

Mason, M. R., Tannemaat, M. R., Malezzy, M. J., and Verhaagen, J. (2011). Gene therapy for the peripheral nervous system: a strategy to repair the injured nerve? Curr. Gene Ther. 11, 75–89.

Naso, M. F., Tomkowicz, B., Perry, W. L., 3rd, and Strohl, W. R. (2017). Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs 31, 317–334.

Richner, M., Bjerrum, O. J., Nykjaer, A., and Vaegter, C. B. (2011). The spared nerve injury (SNI) model of induced mechanical allodynia in mice. J. Vis. Exp. 3092.

Richner, M., Jager, S. B., Siupka, P., and Vaegter, C. B. (2017). Hydraulic extrusion of the spinal cord and isolation of dorsal root ganglia in rodents. J. Vis. Exp. 55226.

Samulski, R. J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.

Savastano, L. E., Laurito, S. R., Fitt, M. R., Rasmussen, J. A., Gonzalez Polo, V., and Patterson, S. I. (2014). Sciatic nerve injury: a simple and subtle model for investigating many aspects of nervous system damage and recovery. J. Neurosci. Methods 227, 166–180.

Stoica, L., Ahmed, S. S., Gao, G., and Sena-Esteves, M. (2013). Gene transfer to the CNS using recombinant adeno-associated virus. Curr. Protoc. Microbiol. Chapter 14, Unit14D 5.

Tervo, D. G., Hwang, B. Y., Viswanathan, S., Gaj, T., Lavzin, M., Ritola, K. D., Lindo, S., Michael, S., Kuleshova, E., Ojala, D., et al. (2016). A designer AAV variant permits efficient retrograde access to projection neurons. Neuron 92, 372–382.

Tosolini, A. P., and Sleigh, J. N. (2020). Intramuscular delivery of gene therapy for targeting the nervous system. Front. Mol. Neurosci. 13, 129.

Towne, C., Pertin, M., Beggha, A. T., Aebischer, P., and Decosterd, I. (2009). Recombinant adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer to nociceptive neurons through different routes of delivery. Mol. Pain 5, S2.

Wang, D., Tai, P. W. L., and Gao, G. (2019). Adeno-associated virus vector as a platform for gene therapy delivery. Nat. Rev. Drug Discov. 18, 358–378.

Yu, H., Fischer, G., and Hogan, Q. H. (2016). AAV-mediated gene transfer to dorsal root ganglion. Methods Mol. Biol. 1382, 251–261.